Mizuho reiterates Outperform on Syndax stock, $43 target

Syndax reported Q3 revenue of $83.3 million, above the $82.41 million forecast, while adjusted loss per share of $0.55 was wider than the expected $0.48; Revuforj revenue was $60.7 million, up 90% year over year and 11% quarter over quarter. Mizuho reiterated Outperform with a $43 price target, viewing transplant data as moderately positive for longer-term NPM1-mutated patient sales, though transplant and recovery may temporarily weigh on sales. The stock was down 38% year to date at $13.10, near its $12.79 52-week low; Syndax ended the quarter with $551 million in cash and investments and maintained its 2026 spending outlook.

Analysis

The key valuation question is whether transplant-related treatment gaps are merely shifting Revuforj revenue across quarters or reducing lifetime treatment exposure. The disclosed maintenance pattern supports the former, but only if patients resume therapy and remain on it longer; neither resumption rates nor duration are established here. Near term, transplant-related pauses can obscure underlying demand and make quarterly growth noisier. Over 6–18 months, documented post-transplant persistence could improve the revenue-per-patient profile and partially offset these interruptions.

The stock’s weakness despite roughly in-line Revuforj sales suggests investors are focused less on launch growth than on earnings quality and the path from sales to cash generation. Do not treat the cited 2.88% gross-margin figure as a standalone read-through to product economics without reconciling its definition and collaboration accounting. Cash and an unchanged spending outlook reduce immediate financing pressure, but a wider-than-expected loss keeps execution risk relevant. Analyst targets are not evidence that the market has mispriced the asset.

The contrarian upside case is that transplant patients are not lost customers but a temporarily interrupted cohort with potentially longer maintenance exposure. The downside is that the interruption is durable attrition, while commercial growth fails to translate into improving economics. The next useful evidence is patient-level resumption and duration, Revuforj sequential growth, Niktimvo contribution economics, and cash burn—not another broad bullish rating.

Key Decisions for Investors

• No immediate directional trade: revenue near expectations and an unquantified maintenance-duration benefit do not yet support underwriting the large gap between the share price and analyst targets.
• Put SNDX on an event-driven watchlist for the next quarterly update. Reassess a measured long only if management provides evidence that post-transplant patients resume therapy and that Revuforj growth remains durable; size against the possibility that reported quarter-to-quarter sales are distorted by treatment pauses.
• Falsify the long thesis if Revuforj sequential growth materially slows, management indicates weak post-transplant resumption or shorter-than-expected treatment duration, spending rises beyond the maintained outlook, or the stock breaks below its reported $12.79 52-week low.
• Before interpreting margin or runway risk, verify the basis of the reported gross-margin figure, cash burn against the $551 million cash-and-investments balance, and the economics attributable to Syndax from Niktimvo collaboration revenue.